All In Biotech

NDA 202428 · Mayne Pharma

Fabior

Tazarotene · Topical · Retinoid

Last checked: Nov 20, 2026Latest source record: May 11, 2012 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

May 11, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

61

15 Phase 3, 0 recruiting

FAERS reports

466

130 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 3, 2026.

FABIOR ® (tazarotene) Foam, 0.1% is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older. FABIOR Foam is a retinoid indicated for the topical treatment of acne vulgaris in patients 12 years of age or older. ( 1 )

Mechanism: Tazarotene is a retinoid prodrug that is converted to its active form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man. Tazarotenic acid binds to all 3 members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARγ but shows relative selectivity for RARβ and RARγ and may modify gene expression. The clinical significance of these findings is unknown. The mechanism of tazarotene action in acne vulgaris is not defined. However, the basis of tazarotene's therapeutic effect in acne may be due to its anti-hyperproliferative,...

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • FABIOR · TAZAROTENE 0.1% · AEROSOL, FOAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tazarotene" as an intervention, any sponsor and status, largest first.

All 61 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective60
  • erythema42
  • skin exfoliation41
  • off label use39
  • application site erythema31
  • rash31
  • pruritus29
  • application site pain27
  • pain23
  • product use in unapproved indication18
  • application site discolouration17
  • burning sensation17

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20061
20073
20083
20092
20103
20114
20122
20135
201437
201515
201619
20177
201846
201945
202031
202125
202240
202375
202435
202528
202638

Recalls

1 FDA enforcement reports for this application.

  • Mar 21, 2018 · Class III · Terminated

    Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fabior (Tazarotene)

2024 spending

$34K

Beneficiaries

16

28 claims

Per beneficiary

$2,111

$12.29 per unit

View as table
YearSpending
2020$114,814
2021$102,741
2022$69,243
2023$78,713
2024$33,784

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 172 on PubMed

Sponsor: Mayne Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.